Table 2.
Emerging biomarker-targeted therapies in ongoing clinical trials for ovarian cancer
| Drug | Target | Trial | Clinical phase | Results |
|---|---|---|---|---|
| Mirvetuximab Sorvtensine | FR alpha | MIRASOL | III |
PFS 5.62 vs 3.98 months OS 16.46 vs 12.75 months |
| Farletuzumab | FR alpha | NCT03386942 | I | ORR 25.0% and 52.4% |
| Luveltamab tazevibulin | FR alpha | STRO-002-GM1 | Ib |
ORR 37.5% PFS 6.1 months |
| Trastuzumab–deruxtecan | HER2 | Destiny-PanTumor02 | Ib |
ORR 45.0% (HER2 3 + 63.6%) PFS 5.9 months (HER2 3 + 12.5 m) OS 13.2 months (HER2 3 + 20.0 m) |
| Nivolumab | MMRd/MSI-H | NCT03241745 | II |
ORR 58.8% PFS 21.6 months OS not reached |
| Pembrolizumab | MMRd/MSI-H | KEYNOTE-158 | II |
ORR 33.3% PFS 3.5 months |
| Adavosertib | CCNE1 amplification | NCT03253679 | II |
ORR 36% PFS 6.3 months |
| CCEN1 overexpression | IGNITE | II | ORR 53% | |
| Raludotatug–deruxtecan | Cadherin-6 | NCT04707248 | I |
ORR 46% PFS 7.9 months |
| Datopotamab–deruxtecan | TROP2 | TROPION-PanTumor03 | II |
ORR 42.9% PFS 5.6 months |
| Sacituzumab–tirumotecan | TROP2 | MK-2870–001 | I/II | ORR 40%mPFS 6.0 mo |